Glenmark Pharma has reported a profit after tax of Rs 46 crore in the third quarter of FY12, a fall of 47% as compared to Rs 86.5 crore in a year ago quarter.
The company reported a forex loss of Rs 102 crore and licensing income of Rs 23.8 crore from Sanofi in the October-December quarter.
Revenues jumped 37.7% to Rs 1,031 crore from Rs 749 crore year-on-year.
EBITDA fell 23% to Rs 103 crore from Rs 134 crore and operating profit margin declined at 10% versus 18% YoY and 21.4% QoQ.
Revenue growth was driven by 11% in India, 56% in US, 58% in Europe and 48% in Latin America.
Margins contracted due to growth from lower margin regions despite adjustment. However, the company is in line to exceed guidance for FY12 - achieved 31% revenue growth for 9MFY12 s guidance of 25% growth.
On quarter-on-quarter basis, revenues fell 2.3% and EBITDA declined 54%; even PAT was down by 18%.
Source: www.moneycontrol.com
Thanks,
Gaurav Agarwal
Head Dealer
DENIP Consultants Pvt Ltd
No comments:
Post a Comment